|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.16 - 5.54|
|52 Week Range||2.61 - 10.91|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 14, 2008|
|1y Target Est||10.25|
In cavernous cold-storage warehouses at Amsterdam's Schiphol Airport, KLM workers are gearing up for a surge next year in COVID-19 vaccine cargos that will need to be flown around the world at ultra-low temperatures. A major hub for pharmaceutical products, Schiphol has already handled some of the vaccines being used in trials and KLM's boss is confident its "cold chain" operations will cope with the influx of cargos as mass inoculations start in earnest. "The short and sweet of it is, yes, we're ready," KLM Chief Executive Pieter Elbers told Reuters.
Countries around the world agonised over new coronavirus curbs ahead of Christmas and other holidays as global infections approached 60 million on Wednesday and U.S. officials pleaded with Americans to stay home over Thanksgiving. The holiday weekend is expected to fuel a surge of infections in the United States, which leads the world with soaring COVID-19 infections and the daily toll on Tuesday climbing above 2,000, the highest 24-hour tally since early May.
Air France-KLM is among airlines gearing up for the challenge of transporting millions of doses of temperature-sensitive COVID-19 vaccines in the midst of a travel slump. Breakthrough vaccines developed by Pfizer and Moderna have yet to win final approval, but the drugmakers, their logistics and cargo providers are not waiting for a green light to activate freight plans. Air France-KLM, which has decades of experience shipping medicines and vaccines in temperature-controlled conditions, is preparing a test run in coming days to fly out dummy vaccine shipments, likely from KLM's Amsterdam-Schiphol hub.